BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

China’s Joint Procurement Office announced steep price cuts for companies that won the tender bids for 25 drugs in the nationwide expansion of its pilot program for centralized procurement of generic and off-patent originator drugs....
BioCentury | Mar 29, 2019
Company News

Luye submits NDA for schizophrenia, bipolar disorder therapy

Luye submitted an NDA to FDA for Rykindo risperidone extended-release microspheres (LY03004) to treat schizophrenia and bipolar disorder. Luye Pharma Group Ltd. (HKSE:2186) hopes to launch the injectable formulation of the generic risperidone in the...
BioCentury | Oct 26, 2018
Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck reported that Lu AF35700 missed the primary...
BioCentury | Oct 25, 2018
Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck slid DKK108.90 (27%) to DKK300 on Thursday...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BioCentury | Aug 3, 2018
Clinical News

FDA approves once-monthly schizophrenia drug from Durect, Indivior

Durect Corp. (NASDAQ:DRRX) and Indivior plc (LSE:INDV) said FDA approved Perseris risperidone (RBP-7000) to treat schizophrenia in adults. The approval triggered a $5 million milestone payment to Durect from Indivior. The companies said Perseris is...
BioCentury | Jul 30, 2018
Company News

FDA approves once-monthly schizophrenia drug from Durect, Indivior

Durect Corp. (NASDAQ:DRRX) and Indivior plc (LSE:INDV) said FDA approved Perseris risperidone (RBP-7000) to treat schizophrenia in adults. The approval triggered a $5 million milestone payment to Durect from Indivior. The companies said Perseris is...
BioCentury | May 11, 2018
Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline....
BioCentury | May 11, 2018
Company News

Luye acquires AstraZeneca antipsychoitic for $538M

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China,...
BioCentury | May 7, 2018
Company News

Luye paying AZ $538M for antipsychotic

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China,...
Items per page:
1 - 10 of 377